Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges.

Authors

• Stephanie M Robert
• Allison Toth
• Sapir Lev
• Stephen G Bowden
• Yao Yu
• Brandon S Imber
• Adrienne Boire
• Joshua Z Drago
• Shanu Modi
• Nelson S Moss

Publication/Presentation Date

9-1-2025

Abstract

The management of brain metastases (BrM) remains a major clinical challenge due to limited drug delivery across the blood-brain barrier (BBB) and the need for simultaneous CNS and systemic disease management, often with competing therapeutic strategies. Antibody-drug conjugates (ADCs) are a promising class of drugs that offers precision therapy by combining the specificity of monoclonal antibodies with potent chemotherapeutics for targeted tumor delivery. This review explores the current landscape of ADCs in BrMs, challenges in BBB penetration, and CNS-specific toxicities, including interactions with radiotherapy and the risk of radiation necrosis.

Volume

174

Issue

3

First Page

541

Last Page

556

ISSN

1573-7373

Published In/Presented At

Robert, S. M., Toth, A., Lev, S., Bowden, S. G., Yu, Y., Imber, B. S., Boire, A., Drago, J. Z., Modi, S., & Moss, N. S. (2025). Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges. Journal of neuro-oncology, 174(3), 541–556. https://doi.org/10.1007/s11060-025-05083-0

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

40471420

Department(s)

Administration and Leadership

Document Type

Article